唑来膦酸

唑来膦酸（CAS 118072-93-8）的公开数据库记录，列此仅供独立核对。

危险化学品分类与危害说明

物理形态与操作说明

• Solid
• Sparingly soluble

公开数据库收录的理化数据

这个物质在各数据库里的编号

数据库记载的用途

• Consumption (g per capita) in the USA (2002): 2.03e-06
• For the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget's Disease.
• Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
• Zoledronate, also known as zoledronic acid, is an antiresorptive medication that belongs to a class of drugs known as bisphosphonates. Zoledronate is administered intravenously (IV) and is commonly prescribed and indicated to treat various metabolic bone disorders, including both malignant and benign diseases. As zoledronate is administered via the IV route, it can be utilized in patients with an intolerance or contraindication to oral bisphosphonates.
• Breast Feeding; Lactation; Bisphosphonates; Bone 密度 Conservation Agents; Diphosphonates;
• Medicines for endocrine disorders

它在各数据库里的别名

Zoledronic acid; 118072-93-8; Zoledronate; Zometa; Reclast; Aclasta; (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; Zoledronic Acid Anhydrous; Anhydrous Zoledronic Acid; CGP 42446; DTXSID0042668; 70HZ18PH24; Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-; ZOL 446; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; NSC-721517

计算机算出的分子描述符

数据库摘要

Zoledronic acid · CAS 118072-93-8 · C5H10N2O7P2. UNII 70HZ18PH24. 溶解度: 3.27e+00 g/L; LogP: -4.2.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。